Jette Tjørnelund
Research Subjects
Jette Tjørnelund has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Claus Cornett
Department of Pharmacy, University of Copenhagen, Universitetsparken 2, Copenhagen 2100, Denmark
2 shared publications - Svend Høime Hansen
Department of Clinical Biochemistry, 3-01-1, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark,
2 shared publications - Ulla Grove Sidelmann
Drug Metabolism, Novo Nordisk A/S, Maaloev, Denmark
2 shared publications A. K. Olsen
Department of Analytical and Pharmaceutical Chemistry, The Royal Danish School of Pharmacy, DK-2100 Copenhagen, Denmark
1 shared publicationE Christiansen
1 shared publicationE. Christensen
Department of Analytical and Pharmaceutical Chemistry, OE Department of Medicinal Chemistry, The Royal Danish School of Pharmacy, Universitetsparken 2, DK-2100 Copenhagen, Denmark Bruker Analytische Messteknik GmbH, Silberstreifen D-76287, Rheinstetten, Germany . Mullegaard Breeding and Research Centre A} S, Tornbjergvej 40, DK-4623 Lille Skensved, Denmark
1 shared publication
Latest Publications
- 1 January 2002
- Published by Taylor & Francis in Xenobiotica
- Vol. 32 (9) , 749-759
Characterization of mixtures of recombinant human cytochrome P450s as a screening model for metabolic stability in drug discovery
1. Recombinant human cytochrome P450 (rh CYP) has become an important screening model in drug metabolism studies due to the high cost of human and animal hepatic tissue. Until now, rh CYPs have been evaluated and used as separate forms, but a mixture of CYP forms comparable with the human liver could be of value in early drug discovery. 2. In the present study, rh CYP2C9, rh CYP2D6 and rh CYP3A4 co-expressed with reductase in Escerichia coli were mixed and evaluated with regards to kinetic properties (K m and V max) . Furthermore, antioxidant was added to investigate whether a free radical scavenger would affect the kinetic parameters. Results were compared with data obtained in human liver microsomes (HLM). 3. Results showed a good correlation between mixed rh CYP data and HLM data for K m and V max. K m varied < 3-fold between matrices for CYP2C9 and CYP3A4, whereas the K m for CYP2D6 varied up to 4.5-fold. V max differed up to 3-fold between matrices for the CYP forms investigated. However, the discrepancy in V max may depend on the anticipated level of each form in HLM. The addition of antioxidant increased V max for CYP2C9 and CYP2D6 by 75 and 50%, respectively, whereas V max for CYP3A4 was unchanged. 4. In conclusion, the rh CYP mixture shows promising results as a predictor of CYP kinetic parameters. Furthermore, addition of antioxidant can in certain cases increase catalytic activity.
- 1 January 2002
- Published by Taylor & Francis in Xenobiotica
- Vol. 32 (9) , 749-759
Characterization of mixtures of recombinant human cytochrome P450s as a screening model for metabolic stability in drug discovery
1. Recombinant human cytochrome P450 (rh CYP) has become an important screening model in drug metabolism studies due to the high cost of human and animal hepatic tissue. Until now, rh CYPs have been evaluated and used as separate forms, but a mixture of CYP forms comparable with the human liver could be of value in early drug discovery. 2. In the present study, rh CYP2C9, rh CYP2D6 and rh CYP3A4 co-expressed with reductase in Escerichia coli were mixed and evaluated with regards to kinetic properties (K m and V max) . Furthermore, antioxidant was added to investigate whether a free radical scavenger would affect the kinetic parameters. Results were compared with data obtained in human liver microsomes (HLM). 3. Results showed a good correlation between mixed rh CYP data and HLM data for K m and V max. K m varied < 3-fold between matrices for CYP2C9 and CYP3A4, whereas the K m for CYP2D6 varied up to 4.5-fold. V max differed up to 3-fold between matrices for the CYP forms investigated. However, the discrepancy in V max may depend on the anticipated level of each form in HLM. The addition of antioxidant increased V max for CYP2C9 and CYP2D6 by 75 and 50%, respectively, whereas V max for CYP3A4 was unchanged. 4. In conclusion, the rh CYP mixture shows promising results as a predictor of CYP kinetic parameters. Furthermore, addition of antioxidant can in certain cases increase catalytic activity.
- 30 December 1998
- Published by Elsevier in Journal of Biochemical and Biophysical Methods
- Vol. 38 (2) , 139-153
Non-aqueous capillary electrophoresis of drugs: properties and application of selected solvents
- 30 December 1998
- Published by Elsevier in Journal of Biochemical and Biophysical Methods
- Vol. 38 (2) , 139-153
Non-aqueous capillary electrophoresis of drugs: properties and application of selected solvents
- 1 June 1997
- Vol. 25 (6) , 725-31
Purification and 1H NMR spectroscopic characterization of phase II metabolites of tolfenamic acid.
Tolfenamic acid, an anti-inflammatory drug (NSAID), is metabolized in vivo to form several oxidative metabolites which are all conjugated with beta-D-glucuronic acid. In this study, the metabolites of tolfenamic acid were identified by 1H nuclear magnetic resonance (NMR) spectroscopy in urine samples obtained on days 7 to 10 from a human volunteer after oral administration of 200 mg of the drug three times per day (steady-state plasma concentration). The metabolites of tolfenamic acid were initially concentrated by preparative solid phase extraction (PSPE) chromatography, thereby removing the endogenous polar compounds that are present in the urine. The individual metabolites were purified by preparative high performance liquid chromatography (HPLC) and then identified using 1H NMR. Both one- and two-dimensional NMR experiments were performed to identify the phase II metabolites of tolfenamic acid; the study shows the applicability of 1H NMR for the identification of drug metabolites in biological fluids. In addition to NMR analysis, two metabolites were also identified by mass spectrometry (MS). The glucuronides of the following parent compounds, N-(2-methyl-3-chlorophenyl)-anthranilic acid (T), N-(2-hydroxymethyl-3-chlorophenyl)-anthranilic acid (1), N-(2-hydroxymethyl-3-chloro-4-hydroxyphenyl)-anthranilic acid (2), N-(2-formyl-3-chlorophenyl) anthranilic acid (3), N-(2-methyl-3-chloro-4-hydroxyphenyl)-anthranilic acid (4), N-(2-methyl-3-chloro-5-hydroxyphenyl)-anthranilic acid (5), N-(2-carboxy-3-chlorophenyl)-anthranilic acid (6), N-(2-hydroxymethyl-3-chlorophenyl)-4-hydroxy-anthranilic acid (7), N-(2-methyl-3-chlorophenyl)-5-hydroxy-anthranilic acid (8), N-(2-methyl-3-chloro-4-metoxyphenyl)-anthranilic acid (9), N-(2-methyl-3-chlorophenyl)-4-hydroxy-anthranilic acid (10), and N-(2-methyl-4-hydroxyphenyl)-anthranilic acid (11) were identified. The phase II metabolites (5-11) had not previously been identified in urine from humans administered tolfenamic acid. The phase I metabolites of the glucuronides 7, 8, 10, and 11 were identified here for the first time. An HPLC method was developed that simultaneously separates all the phase II metabolites identified as well as some phase I metabolites in urine samples obtained after intake of tolfenamic acid.
- 1 June 1997
- Vol. 25 (6) , 725-31
Purification and 1H NMR spectroscopic characterization of phase II metabolites of tolfenamic acid.
Tolfenamic acid, an anti-inflammatory drug (NSAID), is metabolized in vivo to form several oxidative metabolites which are all conjugated with beta-D-glucuronic acid. In this study, the metabolites of tolfenamic acid were identified by 1H nuclear magnetic resonance (NMR) spectroscopy in urine samples obtained on days 7 to 10 from a human volunteer after oral administration of 200 mg of the drug three times per day (steady-state plasma concentration). The metabolites of tolfenamic acid were initially concentrated by preparative solid phase extraction (PSPE) chromatography, thereby removing the endogenous polar compounds that are present in the urine. The individual metabolites were purified by preparative high performance liquid chromatography (HPLC) and then identified using 1H NMR. Both one- and two-dimensional NMR experiments were performed to identify the phase II metabolites of tolfenamic acid; the study shows the applicability of 1H NMR for the identification of drug metabolites in biological fluids. In addition to NMR analysis, two metabolites were also identified by mass spectrometry (MS). The glucuronides of the following parent compounds, N-(2-methyl-3-chlorophenyl)-anthranilic acid (T), N-(2-hydroxymethyl-3-chlorophenyl)-anthranilic acid (1), N-(2-hydroxymethyl-3-chloro-4-hydroxyphenyl)-anthranilic acid (2), N-(2-formyl-3-chlorophenyl) anthranilic acid (3), N-(2-methyl-3-chloro-4-hydroxyphenyl)-anthranilic acid (4), N-(2-methyl-3-chloro-5-hydroxyphenyl)-anthranilic acid (5), N-(2-carboxy-3-chlorophenyl)-anthranilic acid (6), N-(2-hydroxymethyl-3-chlorophenyl)-4-hydroxy-anthranilic acid (7), N-(2-methyl-3-chlorophenyl)-5-hydroxy-anthranilic acid (8), N-(2-methyl-3-chloro-4-metoxyphenyl)-anthranilic acid (9), N-(2-methyl-3-chlorophenyl)-4-hydroxy-anthranilic acid (10), and N-(2-methyl-4-hydroxyphenyl)-anthranilic acid (11) were identified. The phase II metabolites (5-11) had not previously been identified in urine from humans administered tolfenamic acid. The phase I metabolites of the glucuronides 7, 8, 10, and 11 were identified here for the first time. An HPLC method was developed that simultaneously separates all the phase II metabolites identified as well as some phase I metabolites in urine samples obtained after intake of tolfenamic acid.
- 1 January 1997
- Published by Taylor & Francis in Xenobiotica
- Vol. 27 (7) , 667-680
Synthesis, isolation and identification of glucuronides and mercapturic acids of a novel antiparasitic agent, licochalcone A
1. Four glucuronic acidconjugates of licochalcone A(Lica),and their metabolites,have been synthesized using rabbit and pig liver microsomes and purified by preparative hplc. 2. The glucuronides were identified as E-Lica 4′-O-β-glucuronide, E and Z-Lica 4-O-β-glucuronide and a mono-glucuronide conjugate of a β-hydroxylated Lica metabolite. The metabolites were identified by hplc-nmr (one and two-dimensional nmr) as well as hplc-ms. 3. At pH 8·5 Lica reacted with N-acetyl-L-cysteine giving the twoepimeric conjugates, which were then isolated by preparative hplc and identified by one and two-dimensional nmr spectroscopic methods. 4. Only twoglucuronic acid conjugates (E- and Z-Lica 4-O-β-glucuronide) were found in the urine of rat after i.p. administration of a single dose of Lica.
- 1 January 1997
- Published by Taylor & Francis in Xenobiotica
- Vol. 27 (7) , 667-680
Synthesis, isolation and identification of glucuronides and mercapturic acids of a novel antiparasitic agent, licochalcone A
1. Four glucuronic acidconjugates of licochalcone A(Lica),and their metabolites,have been synthesized using rabbit and pig liver microsomes and purified by preparative hplc. 2. The glucuronides were identified as E-Lica 4′-O-β-glucuronide, E and Z-Lica 4-O-β-glucuronide and a mono-glucuronide conjugate of a β-hydroxylated Lica metabolite. The metabolites were identified by hplc-nmr (one and two-dimensional nmr) as well as hplc-ms. 3. At pH 8·5 Lica reacted with N-acetyl-L-cysteine giving the twoepimeric conjugates, which were then isolated by preparative hplc and identified by one and two-dimensional nmr spectroscopic methods. 4. Only twoglucuronic acid conjugates (E- and Z-Lica 4-O-β-glucuronide) were found in the urine of rat after i.p. administration of a single dose of Lica.
- 1 March 1996
- Vol. 3 (2) , 83-7
Nonaqueous capillary electrophoresis in pharmaceutical analysis.
Nonaqueous media have shown to be useful for CE separations. It is possible to obtain high selectivities of closely related compounds without using any additive in the electrophoresis medium. The physicochemical parameters of some selected solvents and their influence on separation are discussed. Separations of small compounds with equal or almost equal charge-to-mass ratios have been performed in both aqueous- and nonaqueous-based media and compared. Examples of the use of nonaqueous media for drug impurity testing are given, and precautions for obtaining quantitative and reproducible analysis in nonaqueous media are discussed.
- 1 March 1996
- Vol. 3 (2) , 83-7
Nonaqueous capillary electrophoresis in pharmaceutical analysis.
Nonaqueous media have shown to be useful for CE separations. It is possible to obtain high selectivities of closely related compounds without using any additive in the electrophoresis medium. The physicochemical parameters of some selected solvents and their influence on separation are discussed. Separations of small compounds with equal or almost equal charge-to-mass ratios have been performed in both aqueous- and nonaqueous-based media and compared. Examples of the use of nonaqueous media for drug impurity testing are given, and precautions for obtaining quantitative and reproducible analysis in nonaqueous media are discussed.